Hans Lee
Sarah Cannon Research Institute (SCRI) Oncology Partners
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hans Lee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:31 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07637578 · A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomaSCRI Development Innovations, LLC · recruiting · Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:31 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.Lancet Oncol · 2020666 citationsRCR 30.2
- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.J Clin Oncol · 2024179 citationsRCR 22.7
- 162 citationsRCR 8.8
- 129 citationsRCR 7.1
- Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma.Biomed Res Int · 201479 citationsRCR 3.0
- Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.Lancet Haematol · 201975 citationsRCR 3.1
- Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.Leukemia · 202162 citationsRCR 3.3
- Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.Blood Cancer J · 202048 citationsRCR 2.0
- Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.Cancer Res Treat · 202037 citationsRCR 1.5
- Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant.J Am Soc Nephrol · 202434 citationsRCR 5.3